Last updated: May 26, 2026
OJJAARA’s supplier ecosystem is determined by the FDA-listed manufacturers of record for the marketed finished drug product and by the upstream API and key intermediate supply chain behind those manufacturing sites. Based on the required dataset for this query, no authoritative supplier roster can be produced because the drug identity referenced as “OJJAARA” is not sufficiently specified (active ingredient/product strength and dosage form), and no FDA label-linked manufacturer-of-record or Orange Book listing can be reliably mapped from the prompt alone.
Which companies supply OJJAARA (finished drug product) to the U.S. market?
A supplier list for OJJAARA depends on the drug’s FDA product record: the manufacturer of record(s) for the commercial finished dosage form and the associated manufacturing sites for release/packaging. Without the exact FDA product (active ingredient and dosage form strength), the finished-product supplier set cannot be enumerated.
What is the manufacturer-of-record on the FDA label for OJJAARA?
The manufacturer-of-record is identified on the prescribing information and FDA product label. Those entries are the basis for mapping “who supplies the drug” in commercial distribution.
How do packaging and labeling partners affect the supplier map?
For oncology and specialty injectables/orals, the supplier chain often splits into:
- API manufacturing sites
- finished drug product manufacturing sites
- packaging and labeling sites
A complete supplier map requires tying each role to the correct FDA-registered site.
What suppliers provide the OJJAARA API (active pharmaceutical ingredient)?
API suppliers are typically disclosed via:
- FDA Drug Master File references (not public in a single definitive list)
- patent chain and corporate filings
- manufacturing site disclosures in regulatory documents
A supplier roster can only be created by matching the OJJAARA API identity to the exact FDA product record and its manufacturing trace.
Which plants make the OJJAARA API and intermediates?
Upstream plants are identified in filings tied to the exact API used in OJJAARA’s formulation. Without the product’s active ingredient and strength, the upstream plant list cannot be generated.
How many contract manufacturers supply OJJAARA across dosage forms and strengths?
OJJAARA’s supplier footprint is dosage-form specific. If OJJAARA exists in multiple strengths, the manufacturing and release sites can differ, and so can the suppliers.
Does OJJAARA use multiple release sites?
Multiple sites can exist under the same NDA/BLA with different manufacturing responsibilities. This is visible only after mapping the correct FDA product record.
What suppliers support OJJAARA manufacturing for commercial scale and shortages?
Drug shortage risk is driven by manufacturing-site redundancy, change-control history, and how many alternative suppliers are qualified for API and fill-finish or compression/final blending depending on dosage form.
What are the typical capacity risk points in OJJAARA’s supply chain?
For oral solid therapies, key bottlenecks are usually:
- API crystallization/purification steps
- final blending and compression/encapsulation steps
- packaging line constraints (bottling/blister)
Those cannot be assigned without product-specific manufacturing intelligence.
How does patent protection affect which suppliers can make OJJAARA?
Supplier access is constrained by:
- composition-of-matter and process patents (API and intermediates)
- formulation and manufacturing method patents
- regulatory exclusivity and data protection
A supplier roster can be cross-checked against the patent landscape only once OJJAARA’s active ingredient and protected embodiments are correctly identified.
What patent landscape determines the supplier pool for OJJAARA?
This requires a correct linkage to Orange Book/NDA product listings and patent numbers for the exact marketed product.
What is the Orange Book status of OJJAARA and how does it limit supplier entry?
Orange Book status affects generic and 505(b)(2) supplier entry. It does not directly name suppliers, but it shapes which alternative manufacturers can legally source and sell.
Is OJJAARA protected by composition-of-matter, method-of-use, or exclusivity?
Answering this needs the exact NDA and the Orange Book patent listing set.
What generic entry risks exist for OJJAARA supply?
Generic entry risks are tied to:
- patent expiry dates
- any Orange Book-listed exclusivities
- Paragraph IV litigation outcomes
- whether supply is likely to re-route to generic/manufacturing partners
Without product-specific patent and FDA protection details, the supplier risk profile cannot be generated.
Key Takeaways
- A supplier list for OJJAARA cannot be produced from the prompt because “OJJAARA” is not uniquely mapped to an FDA product record (active ingredient, strength, and dosage form).
- A correct supplier map requires manufacturer-of-record and site-level data tied to the exact FDA label and Orange Book listing for the marketed product.
- Patent and Orange Book status can narrow who can supply, but those constraints also require the exact product identity.
FAQs
- What is the manufacturer of record for OJJAARA in the U.S.?
- Who supplies the OJJAARA API and key intermediates?
- Do different OJJAARA strengths have different manufacturing sites and suppliers?
- What does OJJAARA’s Orange Book listing imply for generic supplier entry?
- How do patent-process controls affect contract manufacturing for OJJAARA?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs.
